alexa Cultured Red Blood Cells For Transfusion
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

International Conference on Hematology & Blood Disorders
September 23-25, 2013 DoubleTree by Hilton Hotel Raleigh-Durham Airport at RTP, NC, USA

Anna Rita Migliaccio
Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864.S1.004
Blood transfusion represents the first form of cell therapy to enter into clinical use and has played a major role in the development of advanced therapies for genetic form of anemia (that would be otherwise lethal) and for cancer and makes it feasible to perform the extensive surgical procedures developed by modern medicine. In developed countries the blood supply is adequate and sporadically even in excess. However, difficulties exist to finding blood for alloimmunized patients and for patients with rare blood phenotypes. In addition, the human population is progressively ageing. Changes in age affect the blood supply by both increasing demand and reducing donation. It is predicted that if the human population continues to age at the current paste, blood will become scarce by 2050. These considerations establish the need to develop techniques for generation of cultured red blood cells (cRBCs) as transfusion products. The first-in-man administration of cRBCs has raised great excitement that cultured cRBCs may be used for transfusion in the near future. One of the most compelling issues related to production of cRBC is identification of stem cell sources suitable for their generation. This presentation will discuss the use of buffy coats generated as discarded bio-products during the preparation of platelets from blood of donors expressing rare blood group phenotypes as promising source of cRBCs for diagnostic and clinical purposes.
Anna Rita Migliaccio has completed her Ph.D. at the age of 22 years from Naples University, Naples, Italy and has conducted her postdoctoral studies at the TNO, Rijswijk, The Netherlands and the University of Washington, Seattle, WA. Currently, she is Professor of Medicine, at the Tisch Cancer Institute, Mount Sinai School of Medicine, New York. She has published more than 135 papers in reputed journals and serves as editorial board member of prestigious hematology journals including Blood
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version